Retinalamin
Research OnlyA peptide complex extracted from bovine or porcine retinal tissue, developed by Russian scientist Vladimir Khavinson for ophthalmologic applications. Registered as a drug in Russia for retinal dystrophy and age-related macular degeneration. Very limited Western validation exists.
Retinal peptide complex · Eye peptide · Retina bioregulator
8 human studies
- Preclinical
- 44%
- Clinical
- 44%
Based on 18 cited sources
clinically demonstrated · very-low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 48: best human evidence is multiple small open-label / controlled-observational Russian studies (Khvatova 2005 n=33 retinal abiotrophy 15881150; Trofimova 2006 16676805; Dorofeev 2021 OCT-A pilot 33610151; Malakhova 2024 ERG 38450466) — 1A band 22 (>=2 observational studies), but all high RoB (1B 5), total N ~50-300 (1C 6), direct population/route/outcome (1D 11), modest preclinical base with one NULL rabbit study (1E 4). Mechanism 34: undefined bovine/porcine tissue extract with no single defined molecule or measured binding — target only inferred (2A 10), proximal anti-excitotoxic / proliferative signaling partly shown in vitro (12937684, 30830079; 2B 10), weak single-model dose-response (2C 6), in-vivo mammalian confirmation exists but the photochemical rabbit model was negative (34726859; 2D 8). Plausibility 59: mechanism->surrogate (ERG/OCT-A) established with surrogate->benefit inferred and >=1 unproven link from the undefined composition (3A 18), coherent with retinal disease biology (3B 20), same-class Khavinson analogues Cortexin/Epitalon support the effect (3C 13), moderately broad multi-effect claim (3D 8). Global Coverage 40: replicated across several Russian institutes but one country/cluster (4A 13), minimal geographic breadth with only an emerging Italian Epitalon collaboration (4B 6), ~18 studies of moderate diversity (4C 11), registered as a drug by one national regulator, Russia (4D 10). Community Experience 50: negligible Western community/anecdotal signal but >7 years of registered Russian clinical use (5A 8, 5B 23, 5C 8) with no recurring serious adverse signal beyond local injection reactions (5D 11). Effectiveness basis clinical (very-low): human efficacy data exist but are open-label/uncontrolled with modest, largely surrogate endpoints and NULL controlled signals (Dorofeev OCT-A 33610151 no significant difference), so small effect magnitude (E1 9, E2 6, E3 8, E4 5 = 28); adjunctive use only, not superior to standard of care.
The proposed mechanisms of Retinalamin are based primarily on Russian research. As a tissue-derived peptide complex rather than a single defined molecule, precise mechanistic characterization is limited.
How It Works (Simplified)
Retinalamin is theorized to support retinal function through multiple pathways related to its tissue origin:
Stimulates retinal pigment epithelium (RPE) cell function and may promote regenerative processes in damaged retinal tissue.
May influence local growth factors and cytokines that support photoreceptor and retinal ganglion cell survival.
Proposed to improve retinal blood flow and metabolic processes, supporting oxygen and nutrient delivery to retinal cells.
Animal studies suggest protection against programmed cell death in retinal ganglion cells and photoreceptors under stress conditions.
Key Research Context: All mechanistic research originates from Russian institutes. The exact composition of retinalamin varies by batch as it is a tissue extract, making precise molecular characterization impossible. This is a fundamental limitation compared to synthetic peptides with defined sequences.
Important Limitations
- Undefined composition: Not a single molecule but a peptide mixture; exact active components unknown
- No Western validation: All clinical studies are Russian; no independent replication
- Study quality issues: Most trials are open-label without placebo controls or adequate blinding
- Tissue-derived concerns: Animal tissue extracts carry theoretical risks of contamination and immunogenicity
- Administration barriers: Requires injection by trained medical personnel
- Regulatory status: Not approved outside Russia/CIS; considered experimental elsewhere
- Mechanism uncertainty: Without defined sequence, molecular mechanisms remain speculative
Initial treatment phase. In Russian clinical protocols, patients typically receive 5-10 daily injections. Some studies report subjective improvement in visual comfort within the first week of treatment.
PMID:22184988Measurable changes in electrophysiological parameters (ERG) reported by week 2-3 in some studies. Visual acuity improvements may begin to manifest. Full injection course typically completed.
PMID:38450466Peak effect period following completion of treatment course. Russian studies measure outcomes at 4-8 weeks post-treatment. Improvements in visual field sensitivity and contrast sensitivity documented.
PMID:16676805Long-term maintenance phase. Russian protocols often recommend repeat courses every 6-12 months. Duration of effect varies by condition and individual response. No long-term safety data from controlled studies.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Cortexin
CompatibleBoth tissue-derived Khavinson peptide complexes - cortexin for neurological support, retinalamin for retinal function. Often used together in Russian clinical practice for optic nerve conditions.
Epithalon
CompatibleDifferent targets within Khavinson bioregulator framework - epithalon for systemic longevity via telomerase, retinalamin for tissue-specific retinal support.
Thymalin
CompatibleBoth tissue-derived peptide complexes from Khavinson research. Thymalin provides immune modulation while retinalamin targets retinal tissue. No known contraindications.
Semax
CompatibleBoth Russian peptides with neuroprotective properties - Semax via BDNF for general neuroprotection, retinalamin specifically for retinal neurons.
Selank
CompatibleDifferent therapeutic targets - Selank for anxiolytic and nootropic effects, retinalamin for retinal tissue support. No known interactions.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Retinalamin
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.